omeprazole and Lung Neoplasms studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research Excerpts

Excerpt	Relevance	Reference
" Blood samples were collected at prespecified time points for pharmacokinetic analyses."	2.87	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. ( Bui, K; Cassier, PA; Dickinson, PA; Greystoke, A; Lisbon, E; Moreno, V; Plummer, R; So, K; Thomas, K; Vishwanathan, K; Weilert, D; Yap, TA, 2018)
"Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib with AS therapy affected NSCLC outcomes."	1.42	Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. ( Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M, 2015)
"As the bioavailability of erlotinib is dependent on gastric pH, an increase in gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce its bioavailability and efficacy."	1.39	An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. ( Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D, 2013)

Research

Studies (9)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

AUC of AZD9291

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (11.11)	18.2507
2000's	2 (22.22)	29.6817
2010's	4 (44.44)	24.3611
2020's	2 (22.22)	2.80

Authors	Studies
Gao, H	1
Song, Y	1
Ma, J	1
Zhai, J	1
Zhang, Y	1
Qu, X	1
Zhao, T	1
Liu, Y	1
Hao, Y	1
Zhang, W	1
Tao, L	1
Wang, D	1
Li, Y	1
Liu, Z	1
McKenzie, EA	1
Zhao, Q	1
Diao, A	1
Vishwanathan, K	1
Dickinson, PA	1
Bui, K	1
Cassier, PA	1
Greystoke, A	1
Lisbon, E	1
Moreno, V	1
So, K	1
Thomas, K	1
Weilert, D	1
Yap, TA	1
Plummer, R	1
Hilton, JF	1
Tu, D	1
Seymour, L	1
Shepherd, FA	1
Bradbury, PA	1
Jin, UH	1
Lee, SO	1
Pfent, C	1
Safe, S	1
Chu, MP	1
Ghosh, S	1
Chambers, CR	1
Basappa, N	1
Butts, CA	1
Chu, Q	1
Fenton, D	1
Joy, AA	1
Sangha, R	1
Smylie, M	1
Sawyer, MB	1
Barbato, A	1
Panizzolo, C	1
Landi, L	1
Semenzato, R	1
Rugge, M	1
Sawabata, N	1
Maeda, H	1
Takeda, S	1
Inoue, M	1
Koma, M	1
Tokunaga, T	1
Matsuda, H	1
Kikuchi, H	1
Hossain, A	1
Yoshida, H	1
Kobayashi, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label, Randomised, Phase I, Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI[NCT02163733]	Phase 1	38 participants (Actual)	Interventional	2014-11-14	Completed
A Phase I, Fixed Sequence, Open-label, Study to Assess the Pharmacokinetics of AZD9291 in Healthy Male Volunteers When a Single Oral Dose of AZD9291 80 mg is Administered Alone and in Combination With Omeprazole[NCT02224053]	Phase 1	136 participants (Actual)	Interventional	2014-09-30	Completed
Clinical Application of Vagus Nerve Preservation in Minimally Invasive Surgery for Early Lung Cancer[NCT04125979]		120 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Prospective Randomized Controlled Study on the Effects of Vagus Nerve Pulmonary Branch Preservation During Video-assisted Thoracic Surgery Lobectomy in Non-small Cell Lung Cancer: Can it Decrease Postoperative Cough and Pulmonary Complications[NCT04923412]		214 participants (Anticipated)	Interventional	2021-07-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Area under the plasma concentration curve from zero extrapolated to infinity. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

AUC(0-120) of AZD9291

Intervention	nM*h (Geometric Mean)
Fed (High-fat Meal)	11640
Fasted	12530

Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 120 hours. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post AZD9291 dose in Part A.

AUC(0-72) of AZD9291

Intervention	nM*h (Geometric Mean)
Fed (High-fat Meal)	9549
Fasted	9308

Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 72 hours. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours post AZD9291 dose in Part A.

AUC(0-t) of AZD9291

Intervention	nM*h (Geometric Mean)
Fed (High-fat Meal)	7403
Fasted	7345

Area under the plasma concentration curve from time zero to last quantifiable dose. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

CL/F of AZD9291

Intervention	nM*h (Geometric Mean)
Fed (High-fat Meal)	10820
Fasted	10630

Rate and extent of absorption of AZD9291 by assessment of apparent clearance following oral administration. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

Cmax of AZD9291

Intervention	L/h (Geometric Mean)
Fed (High-fat Meal)	13.75
Fasted	12.78

Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

t1/2 of AZD9291

Intervention	nM (Geometric Mean)
Fed (High-fat Meal)	199.6
Fasted	218.0

Pharmacokinetics of AZD9291 by assessment of the terminal half-life. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

Tmax of AZD9291

Intervention	h (Geometric Mean)
Fed (High-fat Meal)	52.82
Fasted	54.64

Pharmacokinetics of AZD9291 by assessment of time to Cmax. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

Vz/F of AZD9291

Intervention	h (Median)
Fed (High-fat Meal)	7.97
Fasted	6.08

Rate and extent of absorption of AZD9291 by assessment of the apprarent volume of distribution. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

AUC(0-120) of AZ5104 and AZ7550

Intervention	L (Geometric Mean)
Fed (High-fat Meal)	1024
Fasted	1019

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of area under the plasma concentration time curve from zero to 120 hours. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post AZD9291 dose in Part A.

AUC(0-72) of AZ5104 and AZ7550

Intervention	nM*h (Geometric Mean)
	AZ5104	AZ7550
Fasted	875.7	411.4
Fed (High-fat Meal)	744.4	373.4

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of area under the plasma concentration time curve from zero to 72 hours. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours post AZD9291 dose in Part A.

AUC(0-t) of AZ5104 and AZ7550

Intervention	nM*h (Geometric Mean)
	AZ5104	AZ7550
Fasted	613.2	266.4
Fed (High-fat Meal)	497.6	235.0

Area under the plasma concentration curve from time zero to last quantifiable dose for AZ5104 and AZ7550 (metabolites to AZD9291). (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

Cmax of AZ5104 and AZ7550

Intervention	nM*h (Geometric Mean)
	AZ5104	AZ7550
Fasted	1132	591.9
Fed (High-fat Meal)	1033	584.5

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of maximum plasma concentration. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

t1/2 of AZ5104 and AZ7550

Intervention	nM (Geometric Mean)
	AZ5104	AZ7550
Fasted	11.95	5.109
Fed (High-fat Meal)	9.163	4.236

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of the terminal half-life. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

Tmax of AZ5104 and AZ7550

Intervention	h (Geometric Mean)
	AZ5104	AZ7550
Fasted	62.89	91.54
Fed (High-fat Meal)	64.74	85.26

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of time to Cmax. (NCT02163733)
Timeframe: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

AUC of AZD9291

Intervention	h (Median)
	AZ5104	AZ7550
Fasted	8.03	10.00
Fed (High-fat Meal)	24.17	24.60

Area under the plasma concentration-time curve from zero to infinity for AZD9291 (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose

CL/F of AZD9291

Intervention	nM.h (Geometric Mean)
AZD9291 and Omeprazole Co-administration	6690
AZD9291 Alone	6269

Assessment of the PK of AZD9291 using the apparent plasma clearance, CL/F (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Cmax of AZD9291

Intervention	L/h (Geometric Mean)
AZD9291 and Omeprazole Co-administration	23.93
AZD9291 Alone	25.55

Rate and extent of absorption of AZD9291 following single oral doses of AZD9291 tablet formulation by assessment of maximum plasma concentration (Cmax). (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Vz/F of AZD9291

Intervention	nM (Geometric Mean)
AZD9291 and Omeprazole Co-administration	127.8
AZD9291 Alone	126.1

Assessment of the PK of AZD9291 using the apparent volume of distribution, Vz/F (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

AUC of AZ5104 and AZ7550

Intervention	L (Geometric Mean)
AZD9291 and Omeprazole Co-administration	2037
AZD9291 Alone	2343

Area under the plasma concentration-time curve from zero to infinity of AZ5104 and AZ7550 (metabolites to AZD9291) (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

AUC(0-72)

Intervention	nM.h (Geometric Mean)
	AZ5104	AZ7750
AZD9291 Alone	550.7	574.9
AZD9291 and Omeprazole Co-administration	556.6	536.5

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from time zero to 72 hours, AUC(0-72) (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours post AZD9291 dose.

AUC(0-t)

Intervention	nM.h (Geometric Mean)
	AZD9291	AZ5104	AZ7550
AZD9291 Alone	4106	304.0	231.3
AZD9291 and Omeprazole Co-administration	4404	301.5	216.5

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using area under the plasma concentration curve from zero extrapolated to o the time of the last quantifiable concentration, AUC(0-t) (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Cmax of AZ5104 and AZ7550

Intervention	nM.h (Geometric Mean)
	AZD9291	AZ5104	AZ7550
AZD9291 Alone	6249	539.2	560.0
AZD9291 and Omeprazole Co-administration	6673	546.5	520.0

Assessment of the PK of AZ5104 and AZ7550 (metabolites to AZD9291) using the maximum plasma concentration, Cmax (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Parent to Metabolite Ratios of AZ5104 and AZ7550 AUC

Intervention	nM (Geometric Mean)
	AZ5104	AZ7550
AZD9291 Alone	5.889	4.402
AZD9291 and Omeprazole Co-administration	5.543	3.913

Assessment of the PK of AZ5104 and AZ7550 AUC using the parent (AZD9291) to metabolite ratios (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Parent to Metabolite Ratios of AZ5104 and AZ7550 Cmax

Intervention	Ratio (Geometric Mean)
	AZ5104	AZ7550
AZD9291 Alone	0.08785	0.09166
AZD9291 and Omeprazole Co-administration	0.08318	0.08019

Assessment of the PK of AZ5104 and AZ7550 Cmax using the parent (AZD9291) to metabolite ratios (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

t(1/2)

Intervention	Ratio (Geometric Mean)
	AZ5104	AZ7550
AZD9291 Alone	0.04671	0.03491
AZD9291 and Omeprazole Co-administration	0.04335	0.03061

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal half-life, t(1/2) (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Tlag

Intervention	h (Geometric Mean)
	AZD9291	AZ5104	AZ7550
AZD9291 Alone	63.60	54.47	72.16
AZD9291 and Omeprazole Co-administration	58.99	51.06	71.34

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using lag time before observation of quantifiable analyte concentrations in plasma, tlag (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Tmax

Intervention	h (Median)
	AZD9291	AZ5104	AZ7550
AZD9291 Alone	0.00	0.00	0.00
AZD9291 and Omeprazole Co-administration	0.00	0.00	0.00

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using time to reach maximum plasma concentration, tmax (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

λz

Intervention	h (Median)
	AZD9291	AZ5104	AZ7550
AZD9291 Alone	6	7	10
AZD9291 and Omeprazole Co-administration	6	8	10

Assessment of the PK of AZD9291 (parent compound), AZ5104 (metabolite) and AZ7550 (metabolite) using the terminal rate constant, λz (NCT02224053)
Timeframe: PK samples collected in both period 1 and 2 at pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, and 504 hours post AZD9291 dose.

Intervention	1/h (Geometric Mean)
	AZD9291	AZ5104	AZ7550
AZD9291 Alone	0.010898	0.012722	0.009606
AZD9291 and Omeprazole Co-administration	0.011748	0.013577	0.009718

Article	Year
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. Journal of clinical pharmacology, 2018, Volume: 58, Issue:4 Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; C	2018
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. Journal of clinical pharmacology, 2018, Volume: 58, Issue:4 Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; C	2018
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. Journal of clinical pharmacology, 2018, Volume: 58, Issue:4 Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; C	2018
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. Journal of clinical pharmacology, 2018, Volume: 58, Issue:4 Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; C	2018

Article	Year
Untargeted metabolomics analysis of omeprazole-enhanced chemosensitivity to cisplatin in mice with non-small cell lung cancer. Chemico-biological interactions, 2022, Jun-01, Volume: 360 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplat	2022
Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis. Investigational new drugs, 2021, Volume: 39, Issue:2 Topics: Animals; Anti-Ulcer Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidas	2021
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:1 Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III	2013
The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC cancer, 2014, Jul-09, Volume: 14 Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Movement; Cell Prolife	2014
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clinical lung cancer, 2015, Volume: 16, Issue:1 Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Ga	2015
Asthma-like syndrome in a teenager. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2003, Volume: 14, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Albuterol; Amoxicillin; Androstadienes; Anti-Ba	2003
Persistent cough following pulmonary resection: observational and empiric study of possible causes. The Annals of thoracic surgery, 2005, Volume: 79, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D	2005
Persistent cough following pulmonary resection: observational and empiric study of possible causes. The Annals of thoracic surgery, 2005, Volume: 79, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D	2005
Persistent cough following pulmonary resection: observational and empiric study of possible causes. The Annals of thoracic surgery, 2005, Volume: 79, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D	2005
Persistent cough following pulmonary resection: observational and empiric study of possible causes. The Annals of thoracic surgery, 2005, Volume: 79, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D	2005
Induction of cytochrome P-450 1A1 by omeprazole in human HepG2 cells is protein tyrosine kinase-dependent and is not inhibited by alpha-naphthoflavone. Archives of biochemistry and biophysics, 1998, Oct-15, Volume: 358, Issue:2 Topics: Benzoflavones; Benzoquinones; Carcinoma, Hepatocellular; Cytochrome P-450 CYP1A1; DNA Topoisomerases	1998

omeprazole and Lung Neoplasms

Research Excerpts

Research

Studies (9)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

AUC of AZD9291

AUC(0-120) of AZD9291

AUC(0-72) of AZD9291

AUC(0-t) of AZD9291

CL/F of AZD9291

Cmax of AZD9291

t1/2 of AZD9291

Tmax of AZD9291

Vz/F of AZD9291

AUC(0-120) of AZ5104 and AZ7550

AUC(0-72) of AZ5104 and AZ7550

AUC(0-t) of AZ5104 and AZ7550

Cmax of AZ5104 and AZ7550

t1/2 of AZ5104 and AZ7550

Tmax of AZ5104 and AZ7550

AUC of AZD9291

CL/F of AZD9291

Cmax of AZD9291

Vz/F of AZD9291

AUC of AZ5104 and AZ7550

AUC(0-72)

AUC(0-t)

Cmax of AZ5104 and AZ7550

Parent to Metabolite Ratios of AZ5104 and AZ7550 AUC

Parent to Metabolite Ratios of AZ5104 and AZ7550 Cmax

t(1/2)

Tlag

Tmax

λz

Trials

Other Studies